FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> H1N1 | iBio | flu | HAC1

iBio shares jump with flu shot clinical trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

iBio's ($IBIO) shares have jumped 21% with the announcement that it has completed the first Phase I clinical trial of its plant-based vaccine for H1N1 influenza, HAC1. The study of the vaccine, produced by iBio's partner the Fraunhofer USA Center for Molecular Biotechnology, aimed to assess the vaccine's safety, as well as looking for early clues to its ability to trigger an immune response against the flu virus.

The study showed that the vaccine was safe and well-tolerated at low and high doses, regardless of whether an adjuvant was used. The vaccine also triggered immune responses, with the best immune response seen in the people who received the highest dose of the vaccine without an adjuvant. This was a similar response to a marketed flu shot.

The vaccine's development is supported by funding from the Defense Advanced Research Projects Agency (DARPA). The vaccine is based on iBio's iBioLaunch platform, which uses plants to produce engineered proteins. The researchers are analyzing the data and are preparing a manuscript for a peer-reviewed journal.

- read the release

Related Articles:
H1N1 provides new universal flu vax hope
Plant-based H1N1 vax starts clinical trial
WHO says H1N1 pandemic has run its course
Up to 70M doses of unused H1N1 vax to be destroyed


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about H1N1   iBio   flu   HAC1